Protective effects mediated by Nrf2 induction have been evidenced also in Alzheimer’s disease models after SFN treatment, or in Huntington’s disease, where the Nrf2 activation contributes to improve mitochondrial function. Here, NFE2L2 is linked to early-onset autosomal dominant Alzheimer disease.